Login / Signup

Clinical and biochemical outcomes in cobalamin C deficiency with use of high-dose hydroxocobalamin in the early neonatal period.

Abigail KacpuraMarta FrigeniKathryn A GuntherLaura Schoch Farach
Published in: American journal of medical genetics. Part A (2022)
This case report describes a patient with early-onset cobalamin C deficiency who was started on treatment with high-dose parenteral hydroxocobalamin after diagnosis at 13 days of life. Prior to diagnosis, initial presenting symptoms included poor feeding, lethargy, apneic episodes, hypothermia, and hypotonia; these symptoms resolved after initiation of medication. Methylmalonic acid and homocysteine levels were trended and significantly improved with treatment. She was maintained on 2 mg/kg/day dosing of hydroxocobalamin. No adverse effects to treatment were observed. At the time of this report, the patient was 19 months of age; she had not manifested common findings of early-onset cobalamin C deficiency, including microcephaly, poor feeding, growth abnormalities, hypotonia, seizures, maculopathy, or neurodevelopmental delay. This report suggests that early initiation of high-dose hydroxocobalamin is safe and effective.
Keyphrases
  • early onset
  • high dose
  • case report
  • late onset
  • low dose
  • healthcare
  • zika virus
  • autism spectrum disorder
  • brain injury
  • intellectual disability
  • metabolic syndrome
  • skeletal muscle